How MSI and TMB Factor into Current Biomarker Testing PanelsVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.
Dr. Jorge Cortes ponders the cost of treatment versus the improvement in the standard of care, asking if what we are gaining is really worth the rising cost.